Impact of allogeneic stem cell transplantation in patients with higher risk myelodysplastic syndromes - PubMed
7 hours ago
- #TP53 mutation
- #Allogeneic stem cell transplantation
- #Myelodysplastic syndromes
- Allogeneic stem cell transplantation (SCT) offers curative potential for higher-risk myelodysplastic syndromes (HR-MDS).
- A retrospective study of 2045 HR-MDS patients (2000-2023) showed 21% underwent SCT, with median overall survival (OS) of 23.9 months and progression-free survival (PFS) of 14.4 months post-SCT.
- The 5-year cumulative incidence (CI) of relapse was 37%, and CI of treatment-related mortality (TRM) was 25%, with no significant differences based on age categories.
- Survival outcomes improved over time, with median OS increasing from 11.8 months (2000-2010) to 40.2 months (2017-2023).
- TP53 status was the most significant predictor of post-SCT OS: patients with TP53-wild type MDS had 69% 5-year OS, while those with TP53 mutations had poor outcomes (OS 9.1 months for monoallelic, 6.8 months for biallelic).
- The study concludes SCT can lead to excellent long-term survival in TP53-wild type HR MDS patients.